Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.54 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.54 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.52 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.48 |
| ▸ | GABRP | O00591 | 2/20 | 0.48 |
| ▸ | GABRD | O14764 | 2/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1117719 | 1.00 | CYP2D6 (0.54) | CYP2D6CYP2C19CYP1A2ALOX15SLC1A3 | |
| SCHEMBL17743413 | 0.97 | CYP2D6 (0.52) | CYP2D6CYP2C19CYP1A2ALOX15SLC1A3 | |
| SCHEMBL8089095 | 0.88 | CYP2D6 (0.47) | CYP2D6CYP2C19CYP1A2ALOX15SLC1A3 | |
| SCHEMBL42967 | 0.88 | — | — | |
| Ammonia Solution, Strong SCHEMBL1014829 | 0.85 | — | — | |
| SCHEMBL17743430 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL563782 | 0.85 | — | — | |
| Water SCHEMBL10853319 | 0.85 | — | — | |
| Fluoride SCHEMBL28171923 | 0.85 | — | — | |
| SCHEMBL1248549 | 0.85 | CYP2D6 (0.46) | CYP2D6CYP2C19CYP1A2ALOX15SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051773-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AXIAL THERAPEUTICS, INC. (US) | 2023-02-16 | — | — | US | disclosed |
| WO-2006117183-A1 | 3 -M0N0- AND 3 , 5-DISUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051773-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | TLR2, TLR3, TLR4 | CYP2D6 4089/4885CYP2C19 4465/4885CYP1A2 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.